About Us
Eurofarma
Ventures
A forward-thinking corporate venture fund dedicated to advancing drug research and development.
Eurofarma Ventures, an integral part of Eurofarma Laboratorios's commitment to innovation, 
our mission is to drive groundbreaking advancements in drug research and development.
We invest in early-stage biotech companies developing transformative medicine across both mature and novel modalities. Committed to closely following and partnering with entrepreneurs, we share a mission of advancing healthcare for the improvement of lives worldwide.
-
US$ 100 million capital commitment from Eurofarma Laboratorios
-
Agnostic of drug modality and therapeutic indication
-
Focus on therapeutics and platform companies
-
Investment stage: Series A and later, occasionally Seed
-
Maximum of US$ 5million to be invested per company over its investment cycle
-
Geography focus: primarily US and Europe
-
Participation in strong syndicate
-
Rome Therapeutics
Rome is unlocking the “repeatome” – the repetitive sequences of the “dark genome” once dismissed as junk. By unlocking the “repeatome”, the company aims to discover new classes of medicines for cancer and autoimmune diseases.
Learn more: rometx.com
-
Abcuro
Clinical stage biotech developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells.
Learn more: abcuro.com
-
Gen-t
Genetic biobank representing the diverse ethnic population of Brazil to provide drug developers & researchers with genetic data for drug discovery.
Learn more: gen-t.science
-
Walden
Company developing first-in-class, disease modifying renal disease therapies that are broadly applicable and combinable with current and emerging treatment options.
Learn more: waldenbiosciences.com
-
Psivant Therapeutics is developing oral treatments for immunological and inflammatory conditions, areas traditionally dominated by injectable biologics, utilizing the QUAISAR platform, which integrates Quantum computing, Artificial Intelligence, and Structure-Activity Relationships.Learn more: psivant.com
-
Abata Therapeutics is developing tissue-specific, autologous T regulatory cell therapies for autoimmune diseases.Learn more: abatatx.com